KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Gross Margin: 2009-2025

Historic Gross Margin for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to 92.23%.

  • Acadia Pharmaceuticals' Gross Margin fell 24.00% to 92.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.92%, marking a year-over-year increase of 31.00%. This contributed to the annual value of 91.46% for FY2024, which is 281.00% down from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Gross Margin is 92.23%, which was up 0.07% from 92.16% recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Gross Margin peaked at 98.59% during Q1 2023, and registered a low of 88.85% during Q1 2024.
  • Over the past 3 years, Acadia Pharmaceuticals' median Gross Margin value was 92.26% (recorded in 2023), while the average stood at 92.81%.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Gross Margin skyrocketed by 645bps in 2022, and later slumped by 974bps in 2024.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Gross Margin stood at 91.78% in 2021, then soared by 645bps to 98.23% in 2022, then slumped by 598bps to 92.26% in 2023, then slumped by 65bps to 91.60% in 2024, then decreased by 24bps to 92.23% in 2025.
  • Its Gross Margin was 92.23% in Q3 2025, compared to 92.16% in Q2 2025 and 91.65% in Q1 2025.